High-dose versus standard-dose quadrivalent influenza vaccine in children 6 to 35 months

Phase 3, randomised trial of Efluelda and Influsplit in influenza (2 arms), sponsored by Sanofi. Primary endpoint: Number of participants with laboratory-confirmed influenza illness caused by any influenza viral types/subtypes in association with a protocol-defined influenza-like illness.